Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy

6Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer. © 2013 Landes Bioscience.

Cite

CITATION STYLE

APA

Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2013, February). Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy. OncoImmunology. https://doi.org/10.4161/onci.22764

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free